TY - JOUR
T1 - Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation
T2 - Mechanisms and results
AU - Elmariah, Hany
AU - Fuchs, Ephraim J.
N1 - Funding Information:
Supported by P01 CA15396 from the U.S. National Cancer Institute .
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/7
Y1 - 2019/7
N2 - Allogeneic blood or marrow transplantation (BMT) is a curative therapy for a number of high-risk hematologic malignancies. Historically, only patients with a human leukocyte antigen (HLA)-matched sibling or unrelated donor were able to receive this therapy, thus excluding many potential transplant recipients. In recent years, partially mismatched related donor, or human leukocyte antigen-haploidentical (haplo) BMT has expanded the donor pool to nearly every patient in need of a transplant, particularly when using post-transplantation cyclophosphamide to promote immune tolerance and prevent graft-versus-host disease. With now over 15 years of clinical experience using this platform, long terms outcomes are well understood. We review the clinical literature and highlight the advantages and disadvantages of haplo BMT with post-transplantation cyclophosphamide.
AB - Allogeneic blood or marrow transplantation (BMT) is a curative therapy for a number of high-risk hematologic malignancies. Historically, only patients with a human leukocyte antigen (HLA)-matched sibling or unrelated donor were able to receive this therapy, thus excluding many potential transplant recipients. In recent years, partially mismatched related donor, or human leukocyte antigen-haploidentical (haplo) BMT has expanded the donor pool to nearly every patient in need of a transplant, particularly when using post-transplantation cyclophosphamide to promote immune tolerance and prevent graft-versus-host disease. With now over 15 years of clinical experience using this platform, long terms outcomes are well understood. We review the clinical literature and highlight the advantages and disadvantages of haplo BMT with post-transplantation cyclophosphamide.
KW - Cyclophosphamide
KW - Graft-versus-host disease
KW - Hematopoietic cell transplantation
KW - Histocompatibility
KW - Human leukocyte antigens
UR - http://www.scopus.com/inward/record.url?scp=85054151190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054151190&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2018.09.002
DO - 10.1053/j.seminhematol.2018.09.002
M3 - Review article
C2 - 31202428
AN - SCOPUS:85054151190
SN - 0037-1963
VL - 56
SP - 183
EP - 189
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - 3
ER -